Literature DB >> 26905271

Quality of life, resource use, and costs related to hip fracture in Estonia.

M Jürisson1, H Pisarev2, J Kanis3, F Borgström4, A Svedbom5,6, R Kallikorm7, M Lember7, A Uusküla2.   

Abstract

UNLABELLED: We assessed the impact of hip fracture on health-related quality of life (HRQoL) and costs in Estonia. The mean 18-month HRQoL loss in quality adjusted life years (QALY) was estimated at 0.31, and the average cumulative cost from a societal perspective was 8146 euros per hip fracture patient.
INTRODUCTION: The aim of this study is to estimate the impact of hip fracture on HRQoL, resource consumption, and cost over 18 months after the fracture among individuals aged over 50 in Estonia.
METHODS: A cohort of 205 hip fracture patients ≥50 years was followed up for 18 months. HRQoL was estimated before fracture (recall), after fracture, and at 4, 12, and 18 months using the EQ-5D instrument. Health care utilization and costs were obtained from a public health insurance fund database; social, informal, and indirect costs were estimated using patient-reported data.
RESULTS: Hip fracture resulted in the mean 18-month HRQoL loss of 0.31 QALYs. The mean 18-months cumulative cost of hip fracture from a societal perspective was estimated at 8146 (95 % CI 6236-10717) euros per patient. Most of the cost was related to health care (56 %) and informal care (33 %), while social care contributed only 5 %. Utilization of outpatient rehabilitation and nursing care was low (8 % of patients).
CONCLUSIONS: The impact of hip fracture on HRQoL and cost was substantial. Despite appropriate inpatient care, utilization of rehabilitation, nursing care, and social care were low and potentially insufficient to meet the needs of patients with low HRQoL. The shortfall may partially explain a remarkably high use of informal care.

Entities:  

Keywords:  Cost of illness; Disease burden; Estonia; Health-related quality of life; Hip fracture; Osteoporosis; Resource use

Mesh:

Year:  2016        PMID: 26905271     DOI: 10.1007/s00198-016-3544-4

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  29 in total

1.  Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries.

Authors:  Hude Quan; Bing Li; Chantal M Couris; Kiyohide Fushimi; Patrick Graham; Phil Hider; Jean-Marie Januel; Vijaya Sundararajan
Journal:  Am J Epidemiol       Date:  2011-02-17       Impact factor: 4.897

Review 2.  A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions.

Authors:  L Si; T M Winzenberg; B de Graaff; A J Palmer
Journal:  Osteoporos Int       Date:  2014-02-22       Impact factor: 4.507

3.  The ICD-10 Charlson Comorbidity Index predicted mortality but not resource utilization following hip fracture.

Authors:  Barbara Toson; Lara A Harvey; Jacqueline C T Close
Journal:  J Clin Epidemiol       Date:  2014-10-28       Impact factor: 6.437

Review 4.  Geographic trends in incidence of hip fractures: a comprehensive literature review.

Authors:  S Y Cheng; A R Levy; K A Lefaivre; P Guy; L Kuramoto; B Sobolev
Journal:  Osteoporos Int       Date:  2011-04-12       Impact factor: 4.507

5.  Costs and quality of life associated with osteoporosis-related fractures in Sweden.

Authors:  Fredrik Borgström; Niklas Zethraeus; Olof Johnell; Lars Lidgren; Sari Ponzer; Olle Svensson; Peter Abdon; Ewald Ornstein; Karl Lunsjö; Karl Göran Thorngren; Ingemar Sernbo; Clas Rehnberg; Bengt Jönsson
Journal:  Osteoporos Int       Date:  2005-11-09       Impact factor: 4.507

6.  Fragility fracture-related direct medical costs in the first year following a nonvertebral fracture in a managed care setting.

Authors:  Robert L Ohsfeldt; Natalie N Borisov; Richard L Sheer
Journal:  Osteoporos Int       Date:  2005-09-29       Impact factor: 4.507

7.  Burden of high fracture probability worldwide: secular increases 2010-2040.

Authors:  A Odén; E V McCloskey; J A Kanis; N C Harvey; H Johansson
Journal:  Osteoporos Int       Date:  2015-05-28       Impact factor: 4.507

8.  Mortality after osteoporotic fractures.

Authors:  O Johnell; J A Kanis; A Odén; I Sernbo; I Redlund-Johnell; C Petterson; C De Laet; B Jönsson
Journal:  Osteoporos Int       Date:  2003-10-30       Impact factor: 4.507

9.  The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)--quality of life during the first 4 months after fracture.

Authors:  F Borgström; I Lekander; M Ivergård; O Ström; A Svedbom; V Alekna; M L Bianchi; P Clark; M D Curiel; H P Dimai; M Jürisson; R Kallikorm; O Lesnyak; E McCloskey; E Nassonov; K M Sanders; S Silverman; M Tamulaitiene; T Thomas; A N A Tosteson; B Jönsson; J A Kanis
Journal:  Osteoporos Int       Date:  2013-01-10       Impact factor: 4.507

10.  Economic burden of osteoporotic fractures in Austria.

Authors:  Hans Peter Dimai; Kurt Redlich; Monika Peretz; Fredrik Borgström; Uwe Siebert; Jörg Mahlich
Journal:  Health Econ Rev       Date:  2012-06-27
View more
  9 in total

1.  Comparing three machine learning approaches to design a risk assessment tool for future fractures: predicting a subsequent major osteoporotic fracture in fracture patients with osteopenia and osteoporosis.

Authors:  B C S de Vries; J H Hegeman; W Nijmeijer; J Geerdink; C Seifert; C G M Groothuis-Oudshoorn
Journal:  Osteoporos Int       Date:  2021-01-07       Impact factor: 4.507

2.  Socio-economic inequalities in fragility fracture outcomes: a systematic review and meta-analysis of prognostic observational studies.

Authors:  G Valentin; S E Pedersen; R Christensen; K Friis; C P Nielsen; A Bhimjiyani; C L Gregson; B L Langdahl
Journal:  Osteoporos Int       Date:  2019-08-30       Impact factor: 4.507

3.  Health-related quality of life during the first year after a hip fracture: results of the Mexican arm of the International Cost and Utility Related to Osteoporotic Fractures Study (MexICUROS).

Authors:  L Guirant; F Carlos; D Curiel; J A Kanis; F Borgström; A Svedbom; P Clark
Journal:  Osteoporos Int       Date:  2018-02-20       Impact factor: 4.507

4.  Early postoperative Barthel index score and long-term walking ability in patients with trochanteric fractures walking independently before injury: a retrospective cohort study.

Authors:  Takahiro Inui; Yoshinobu Watanabe; Yoshiaki Kurata; Takashi Suzuki; Kentaro Matsui; Keisuke Ishii; Taketo Kurozumi; Hirotaka Kawano
Journal:  Arch Orthop Trauma Surg       Date:  2020-07-23       Impact factor: 3.067

5.  Denosumab, raloxifene, romosozumab and teriparatide to prevent osteoporotic fragility fractures: a systematic review and economic evaluation.

Authors:  Sarah Davis; Emma Simpson; Jean Hamilton; Marrissa Martyn-St James; Andrew Rawdin; Ruth Wong; Edward Goka; Neil Gittoes; Peter Selby
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

6.  The impact of hip fracture on mortality in Estonia: a retrospective population-based cohort study.

Authors:  Mikk Jürisson; Mait Raag; Riina Kallikorm; Margus Lember; Anneli Uusküla
Journal:  BMC Musculoskelet Disord       Date:  2017-06-05       Impact factor: 2.362

7.  Investigation and management of osteoporosis in aged trauma patients: a treatment algorithm adapted to the German guidelines for osteoporosis.

Authors:  Carl Neuerburg; Lena Mittlmeier; Ralf Schmidmaier; Christian Kammerlander; Wolfgang Böcker; Wolf Mutschler; Ulla Stumpf
Journal:  J Orthop Surg Res       Date:  2017-06-08       Impact factor: 2.359

8.  Quality of life after hip fracture: a 12-month prospective study.

Authors:  Francisco Javier Amarilla-Donoso; Raul Roncero-Martin; Jesus Maria Lavado-Garcia; Rosaura Toribio-Felipe; Jose Maria Moran-Garcia; Fidel Lopez-Espuela
Journal:  PeerJ       Date:  2020-06-16       Impact factor: 2.984

9.  Associations of body mass index and diabetes with hip fracture risk: a nationwide cohort study.

Authors:  Hsiu-Ling Huang; Cheng-Chin Pan; Yu-Fen Hsiao; Ming-Chih Chen; Chuan-Yu Kung; Pei-Tseng Kung; Wen-Chen Tsai
Journal:  BMC Public Health       Date:  2018-11-29       Impact factor: 3.295

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.